PMID- 26768921
OWN - NLM
STAT- MEDLINE
DCOM- 20160928
LR  - 20220331
IS  - 1476-5454 (Electronic)
IS  - 0950-222X (Print)
IS  - 0950-222X (Linking)
VI  - 30
IP  - 2
DP  - 2016 Feb
TI  - The design and validation of an optical coherence tomography-based classification 
      system for focal vitreomacular traction.
PG  - 314-24; quiz 325
LID - 10.1038/eye.2015.262 [doi]
AB  - PURPOSE: To develop and validate a classification system for focal vitreomacular 
      traction (VMT) with and without macular hole based on spectral domain optical 
      coherence tomography (SD-OCT), intended to aid in decision-making and 
      prognostication. METHODS: A panel of retinal specialists convened to develop this 
      system. A literature review followed by discussion on a wide range of cases 
      formed the basis for the proposed classification. Key features on OCT were 
      identified and analysed for their utility in clinical practice. A final 
      classification was devised based on two sequential, independent validation 
      exercises to improve interobserver variability. RESULTS: This classification tool 
      pertains to idiopathic focal VMT assessed by a horizontal line scan using SD-OCT. 
      The system uses width (W), interface features (I), foveal shape (S), retinal 
      pigment epithelial changes (P), elevation of vitreous attachment (E), and inner 
      and outer retinal changes (R) to give the acronym WISPERR. Each category is 
      scored hierarchically. Results from the second independent validation exercise 
      indicated a high level of agreement between graders: intraclass correlation 
      ranged from 0.84 to 0.99 for continuous variables and Fleiss' kappa values ranged 
      from 0.76 to 0.95 for categorical variables. CONCLUSIONS: We present an OCT-based 
      classification system for focal VMT that allows anatomical detail to be 
      scrutinised and scored qualitatively and quantitatively using a simple, pragmatic 
      algorithm, which may be of value in clinical practice as well as in future 
      research studies.
FAU - Steel, D H W
AU  - Steel DH
AD  - Sunderland Eye Infirmary, Sunderland, UK.
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, UK.
FAU - Downey, L
AU  - Downey L
AD  - Ophthalmology Department, Hull and East Yorkshire Eye Hospital, Hull and East 
      Yorkshire NHS Trust, Hull, UK.
FAU - Greiner, K
AU  - Greiner K
AD  - Ophthalmology Department, Aberdeen Royal Infirmary, Aberdeen, UK.
FAU - Heimann, H
AU  - Heimann H
AD  - St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK.
FAU - Jackson, T L
AU  - Jackson TL
AD  - Department of Ophthalmology, School of Medicine, King's College London, London, 
      UK.
FAU - Koshy, Z
AU  - Koshy Z
AD  - Department of Ophthalmology, University Hospital Ayr, Ayr, UK.
FAU - Laidlaw, D A H
AU  - Laidlaw DA
AD  - Ophthalmology Department, St Thomas' Hospital, London, UK.
FAU - Wickham, L
AU  - Wickham L
AD  - Ophthalmology Department, Moorfields Eye Hospital, London, UK.
FAU - Yang, Y
AU  - Yang Y
AD  - School of Life and Health Sciences, Aston University, Birmingham, UK.
LA  - eng
GR  - Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20160115
PL  - England
TA  - Eye (Lond)
JT  - Eye (London, England)
JID - 8703986
SB  - IM
MH  - Fovea Centralis
MH  - Humans
MH  - Research Design
MH  - Retina/*pathology
MH  - Retinal Diseases/*classification
MH  - Tissue Adhesions/classification
MH  - Tomography, Optical Coherence/*classification
MH  - Visual Acuity
MH  - Vitreous Body/*pathology
MH  - Vitreous Detachment/*classification
PMC - PMC4763137
COIS- This study group was convened by Alcon, which distributes ocriplasmin in the UK 
      on behalf of Thrombogenics. Neither Thrombogenics nor Alcon had input in the 
      design of the study, manuscript preparation, or editorial review and neither were 
      invited to review the manuscript prior to submission. Steel DHW is a consultant 
      to Alcon and advisor to Novartis and Bayer. Jackson TL is a consultant to 
      Thrombogenics and advisor to Alcon, Bausch & Lomb, and DORC. Yang Y is a 
      consultant to Bayer and Alimera Sciences and advisor to Alcon, Thrombogenics, 
      Allergan, and Novartis. Downey L, Laidlaw DAH, Koshy Z, Heimann H, Wickham L, and 
      Greiner K have acted as advisors to Alcon and Thrombogenics regarding 
      ocriplasmin.
EDAT- 2016/01/16 06:00
MHDA- 2016/09/30 06:00
PMCR- 2017/02/01
CRDT- 2016/01/16 06:00
PHST- 2015/07/08 00:00 [received]
PHST- 2015/10/13 00:00 [accepted]
PHST- 2016/01/16 06:00 [entrez]
PHST- 2016/01/16 06:00 [pubmed]
PHST- 2016/09/30 06:00 [medline]
PHST- 2017/02/01 00:00 [pmc-release]
AID - eye2015262 [pii]
AID - 10.1038/eye.2015.262 [doi]
PST - ppublish
SO  - Eye (Lond). 2016 Feb;30(2):314-24; quiz 325. doi: 10.1038/eye.2015.262. Epub 2016 
      Jan 15.